Hormonal
The presence of satellite cells reduces ex vivo skeletal muscle force production specifically during the morning, whereas this effect is absent in the afternoon.
If you are training for maximum force output, be aware that your muscles may naturally produce less force in the morning due to circadian regulation. This is not a sign of weakness, but a biological rhythm. If possible, schedule heavy strength training in the afternoon when this circadian suppression is absent.
Morning-SC þ animals demonstrated ~25%–30% reductions in tetanic/eccentric specific forces... We conclude that force production is reduced in the presence of SCs in the morning but not in the afternoon, suggesting that SCs may have a time-of-day influence over contractile function.
Why this rating
The study uses an established mouse model with clear statistical significance (P < 0.05) for the primary outcome, but it is an ex vivo study on mice, limiting direct human applicability.
Source
Time-of-day effects on ex vivo muscle contractility following short-term satellite cell ablation
Ryan E. Kahn et al. · American Journal of Physiology-Cell Physiology · 2024
DOI 10.1152/ajpcell.00157.2024
More from this paper
- The reduced force production in the morning associated with satellite cells results in significantly less contractile injury (force loss and dystrophin-negative fibers) following eccentric exercise.Moderate
- The reduced force production in the morning is mechanistically linked to lower calcium availability for contractile units, as indicated by reduced caffeine-induced contracture force.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →